Drugs Made In America Acquisition II Corp. (DMIIR) Stock Overview
Explore Drugs Made In America Acquisition II Corp.’s financial performance, market position, analyst ratings, and future outlook.
Drugs Made In America Acquisition II Corp. (DMIIR)
Key Financials
Key Financials
Market Cap
3.2M
P/E Ratio
33.70
EPS (TTM)
$0.20
ROE
0.03%
DMIIR Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Drugs Made In America Acquisition II Corp.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of DMIIR on the NASDAQ shows an RSI of 39.50, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.02 for the NASDAQ listing.
Key metrics behind Drugs Made In America Acquisition II Corp.'s NASDAQ-traded stock include a P/E ratio of 33.70 and a market capitalization of 3.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of DMIIR on the NASDAQ.